The Journal of Allergy and Clinical Immunology: 90 years strong

The Journal of Allergy was launched in November 1929. The inaugural issue had 6 original articles covering asthma, ragweed pollen, bacterial allergy, a case report, sinusitis, and classification of specific sensitivities. The first editorial emphasized that the  Journal “has been launched as a medium for the presentation of papers concerning the clinical aspects of specific hypersensitivities in human beings.”1 Twenty years later, an editorial celebrating that anniversary stated, “A new era in allergy is coming into being, due to the ‘rediscover y’ that human hypersensitiveness may be responsible for the symptoms of rheumatic fever, acute nephritis, arteritis, and a variety of clinical disorders……Allergy as applied to such situations has the same validity as it has in hay fever, for the lesions of each are mediated by immune mechanism s.”2 One can argue that this was a visionary approach to the scope and future of the specialty, foreshadowing the era of clinical immunology.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Tags: Editorial Source Type: research

Related Links:

ConclusionsThis large observational study based on claims data reliably identified subjects with COPD treated with open TT and their burden on the NHS. Moreover, it could describe the real clinical management of the open TT, before the marketing of the fixed one. These findings are useful for health policymakers in order to promote the appropriate utilization of both currently marketed and future therapies.
Source: Pulmonary Pharmacology and Therapeutics - Category: Respiratory Medicine Source Type: research
Publication date: Available online 21 February 2020Source: Pulmonary Pharmacology &TherapeuticsAuthor(s): Fang Yi, Lina Han, Baojuan Liu, Xu Zhang, Yongxin Xue, Wei Luo, Qiaoli Chen, Kefang LaiAbstractBackgroundNot all patients with cough variant asthma (CVA) show responsiveness to bronchodilators (RB) in clinic. Whether there are specific clinical and pathophysiological features can indicate RB in patients with CVA needs further investigation. Thus, we aimed to investigate the RB in patients with CVA and associated factors.MethodsForty-two CVA patients were randomized in a 2:1 ratio to receive oral bambuterol hydrochl...
Source: Pulmonary Pharmacology and Therapeutics - Category: Respiratory Medicine Source Type: research
Even if children ultimately get caught up on their vaccines after early delays, they remain susceptible to vaccine-preventable diseases for longer right when they're most vulnerable to complications.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Pediatrics News Source Type: news
The Houston ENT&Allergy Clinic not only slashed its no-show rates, but also increased its referral conversion by 35%, which translated to an additional $500,000 in annual revenue.
Source: Healthcare ITNews Videos - Category: Information Technology Tags: Patient Engagement Telehealth Source Type: video
ConclusionsFitness tracker sleep efficiency and wake counts demonstrate clinical utility as predictive of asthma-specific night-time wakening and daily FEV1. Fitness tracker sleep data demonstrated predictive capability for daily asthma outcomes.
Source: Heart and Lung: The Journal of Acute and Critical Care - Category: Respiratory Medicine Source Type: research
A narrow band of proteins that run through dozens of food allergies helped a Peninsula startup swallow $60 million from a syndicate of investors — including high-powered families — to develop a broad food allergy treatment. Alladapt Immunotherapeutics Inc. — a Menlo Park company launched in 2018 by early 23andMe Inc. executive Ashley Dombkowski — expects to use the Series C funding to take its lead drug into a clinical trial later t his year. The oral drug is designed to provoke an immune…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
Condition:   Corona Virus Infection Interventions:   Other: Placebo;   Drug: Remdesivir Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 20 February 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Susann Forkel, Timo Buhl
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Publication date: Available online 6 February 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Khalaf Kridin, Yael Renert-Yuval, Emma Guttman-Yassky, Arnon D. CohenBackgroundEvidence of TH1/IFN-γ overactivation as a major pathogenic driver somewhat conflicts with data supporting robust allergic background in patients with alopecia areata (AA). Previous investigations of immunological dysregulations show that both TH1- and TH2-related markers are overexpressed in AA. Clinical correlations in large populations may shed light on the immune pathways most likely to result in the clinical p...
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
More News: Allergy | Allergy & Immunology | Asthma | Hay Fever | Nephritis | Rheumatology | Sinusitis